The coronavirus disease 2019 (COVID-19) pandemic caused
by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a significant
health issue globally. Point-of-care (POC) testing that can offer
a rapid and accurate diagnosis of SARS-CoV-2 at the early stage of
infection is highly desirable to constrain this outbreak, especially
in resource-limited settings. Herein, we present a G-quadruplex DNAzyme-based
electrochemical assay that is integrated with a sequential flow controllable
microfluidic device for the detection of SARS-CoV-2 cDNA. According
to the detection principle, a pyrrolidinyl peptide nucleic acid probe
is immobilized on a screen-printed graphene electrode for capturing
SARS-CoV-2 DNA. The captured DNA subsequently hybridizes with another
DNA probe that carries a G-quadruplex DNAzyme as the signaling unit.
The G-quadruplex DNAzyme catalyzes the H2O2-mediated
oxidation of hydroquinone to benzoquinone that can be detected using
square-wave voltammetry to give a signal that corresponds to the target
DNA concentration. The assay exhibited high selectivity for SARS-CoV-2
DNA and showed a good experimental detection limit at 30 pM. To enable
automation, the DNAzyme-based assay was combined with a capillary-driven
microfluidic device featuring a burst valve technology to allow sequential
sample and reagent delivery as well as the DNA target hybridization
and enzymatic reaction to be operated in a precisely controlled fashion.
The developed microfluidic device was successfully applied for the
detection of SARS-CoV-2 from nasopharyngeal swab samples. The results
were in good agreement with the standard RT-PCR method and could be
performed within 20 min. Thus, this platform offers desirable characteristics
that make it an alternative POC tool for COVID-19 diagnosis.